Skip to main content

Editorial Board

Editor-in-Chief
Andrea Allmendinger, PhD
Roche/Genentech (Basel, Switzerland); University of Freiburg (Germany)
ORCID: 0000-0002-8250-0978

Editors                                 
Suzanne D'Addio, Merck, Branchburg, NJ USA
Hanns-Christian Mahler, Frankfurt University, Frankfurt, Germany; Bionter, Riehen, Switzerland
Dominik Witzigmann, NanoMedicines Innovation Network (NMIN) & NanoVation Therapeutics, Vancouver, Canada
Daniel Yin, Gilead Sciences, Foster City, CA USA

Social Media Editor (@AAPSOPEN)
Harsh Shah, J-Star Research Inc., Cranbury, NJ USA 
                                               
Editorial Board                                 
Ian Blagbrough, University of Bath, Bath, UK
Ahmed Besheer, Lonza, Basel, Switzerland
Ana Sara Cordeiro, De Montfort University, Leicester, UK
Tapan Das, Bristol Myers Squibb, New Brunswick, NJ USA
Binodh DeSilva, Bristol Myers Squibb, New Brunswick, NJ USA
Vivian Gray, VA Gray Consulting Inc. Hockessin, DE USA
Timothy Hickling, Roche/Genentech, Basel, Switzerland
Kim Huynh-Ba, Pharmalytik, Newark, DE USA
Hyunyoung (Young) Jeong, Purdue University, West Lafayette, IN USA
Tarik Khan, Roche/Genentech, Basel, Switzerland
Prasanna Kolluru, Medefil, Glendale Heights, IL USA
John Lough, University of Sunderland, Sunderland, UK
Christopher McCurdy, University of Florida, Gainesville, FL USA
Ehab Moussa, Abbvie, Mettawa, IL USA
Arnab Mukherjee, Pfizer, New London, CT USA
Anette Müllertz, University of Copenhagen, Copenhagen, Denmark
Ajit Narang, Roche/Genentech, San Francisco, CA USA
Douhai Pan, Bristol Myers Squibb, New Brunswick, NJ USA
Komal Patel, Kenox Pharmaceuticals, Monmouth Junction, NJ USA
Changquan Calvin Sun, University of Minnesota, Minneapolis, MN USA
Harsh Shah, J-STAR Research Inc., Cranbury, NJ USA
Mehran Yazdanian, Teva Pharmaceuticals, Philadelphia, PA US
Qi Tony Zhou, Purdue University, West Lafayette, IN USA

AAPS
Catherine Abbott, AAPS, United States of America
Matthew Baughman, AAPS, United States of America

Past Editor-in-Chief
(2015 - 2019 May) Christopher M. Riley, Riley & Rabel Consulting Services, Inc., United States of America

Affiliated with

Annual Journal Metrics

  • Speed
    65 days to first decision for reviewed manuscripts only
    54 days to first decision for all manuscripts
    112 days from submission to acceptance
    24 days from acceptance to publication

    Usage 
    33,152 Downloads
    24 Altmetric Mentions